Addex Therapeutics Ltd. | Ownership
Companies that own Addex Therapeutics Ltd.
Credit Suisse Asset Management (Schweiz) AG
1,627,985
5.7%
1,627,985
0.01%
04/10/2018
Caxton Corp.
1,597,444
5.59%
1,597,444
4.25%
04/06/2018
Herculis Partners SA
457,865
1.6%
-124,830
6.89%
02/06/2018
Apo Asset Management GmbH
131,345
0.46%
104,345
0.01%
06/29/2018
UBS AG (Investment Management)
69,000
0.24%
5,000
0%
09/04/2018
Zürcher Kantonalbank (Investment Management)
57,077
0.2%
173
0%
07/31/2018
Pictet Asset Management SA
33,397
0.12%
0
0%
03/31/2018
BlackRock Asset Management Schweiz AG
25,343
0.09%
0
0%
09/07/2018
AcomeA SGR SpA
15,315
0.05%
2,815
0.01%
10/31/2017
Graubündner Kantonalbank (Private Banking)
1,756
0.01%
-3
0%
07/31/2018
| Address |
12, Chemin des Aulx
Geneva Geneve (Geneva) 1228
Switzerland
|
|
Employees
|
- |
| Website |
http://www.addextherapeutics.com |
| Updated |
07/08/2019 |
| Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland. |
